Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to -$374000.0.

  • Pharma's Cash from Investing Activities fell 47538.46% to -$374000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$40000.0, marking a year-over-year increase of 9310.34%. This contributed to the annual value of -$442000.0 for FY2025, which is 3943.22% down from last year.
  • As of Q3 2025, Pharma's Cash from Investing Activities stood at -$374000.0, which was down 47538.46% from $580000.0 recorded in Q2 2025.
  • Pharma's 5-year Cash from Investing Activities high stood at $1.9 million for Q1 2021, and its period low was -$553000.0 during Q1 2022.
  • Its 5-year average for Cash from Investing Activities is $20947.4, with a median of -$65000.0 in 2024.
  • As far as peak fluctuations go, Pharma's Cash from Investing Activities plummeted by 252000.0% in 2024, and later soared by 54274.81% in 2025.
  • Quarter analysis of 5 years shows Pharma's Cash from Investing Activities stood at -$49000.0 in 2021, then skyrocketed by 65.31% to -$17000.0 in 2022, then tumbled by 258.82% to -$61000.0 in 2023, then tumbled by 70.49% to -$104000.0 in 2024, then tumbled by 259.62% to -$374000.0 in 2025.
  • Its last three reported values are -$374000.0 in Q3 2025, $580000.0 for Q2 2025, and -$142000.0 during Q1 2025.